Article Information
History
- July 31, 2020.
Copyright
The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Esther Arnaiz1,2,#,
- Ana Miar1,3,#,
- Antonio Gregorio Dias Junior4,5,
- Naveen Prasad3,
- Ulrike Schulze6,
- Dominic Waithe6,
- Jan Rehwinkel4 and
- Adrian L. Harris1,*
- 1Department of Medical Oncology, Molecular Oncology Laboratories, Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Oxford, OX3 9DS, UK
- 2Cambridge Institute for Therapeutic Immunology & Infectious Disease. Jeffrey Cheah Biomedical Centre. Puddlecombe Way, Cambridge, CA CB20AW, UK
- 3Department of Oncology, Old Road Campus Research Building, University of Oxford, Oxford, OX3 7DQ, UK
- 4Medical Research Council Human Immunology Unit, Medical Research Council Weatherall Institute of Molecular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford OX3 9DS, UK
- 5Division of Infectious Diseases and Vaccinology, School of Public Health, University of California, Berkeley, USA
- 6Radcliffe Department of Medicine, Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Oxford, OX3 9DS, UK
- ↵*To whom correspondence should be addressed: Adrian L. Harris Department of Oncology, Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, OX3 9DS, UK. E-mail: adrian.harris{at}oncology.ox.ac.uk. Phone: +44 (0)1865 222457 (PA).
↵# equal contribution